| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
Purity: ≥98%
| ln Vitro |
DODAB-based liposomal formulations have demonstrated efficient gene delivery capabilities in vitro. DODAB:monoolein (MO) lipoplexes (at molar ratios of 4:1, 2:1, and 1:1) successfully mediated transfection of mammalian 293T cells with plasmid DNA, showing little cytotoxicity while enabling efficient pDNA compaction and intracellular delivery. Fluorescence microscopy confirmed that these lipoplexes could access the cytosol and deliver pDNA to the nucleus. In cytokine delivery applications, DODAB:MO (1:2) liposomes encapsulating leukemia inhibitory factor (LIF) at 0.25 µM resulted in an approximately 20% increase in mouse myoblast cell proliferation after 48 hours of incubation compared to free LIF. The DODAB:MO nanosystem also protected its cargo for up to 6 hours when exposed to serum. Additionally, DODAB has been used as an immunoadjuvant, forming stable complexes (80–100 nm hydrodynamic diameter) with various protein antigens including BSA, 18/14-kDa Tcra antigens, and M. leprae hsp-18 kDa recombinant protein.
In life science-related research, dimethyldioctadecylammonium (bromide) is a biochemical reagent that can be utilized as an organic substance or biological material. |
|---|---|
| ln Vivo |
In animal models, DODAB-based liposomes have shown potent immunostimulatory activity. DODAB liposomes containing Ag85B-ESAT-6 antigen induced antigen deposition at intramuscular or subcutaneous injection sites in mice, increasing immune cell exposure to the antigen. In a guinea pig model of Mycobacterium tuberculosis infection, administration of mycobacterial lipid antigens (Ac2SGL and PIM2) formulated in DODAB liposomes reduced spleen bacterial load and decreased the number of lung and spleen lesions. DODAB/protein antigen complexes induced significant cellular immune responses in mice, including delayed-type hypersensitivity reactions (measured by footpad swelling) and cytokine responses, although only weak IgG production was observed. The DODAB:MO (1:2) nanosystem has been validated for multiple biomedical applications including pDNA, siRNA, drug, and vaccine antigen delivery.
|
| Enzyme Assay |
The DNA compaction efficiency of DODAB-based lipoplexes has been studied using ethidium bromide (EtBr) exclusion assays. In this assay, pDNA is mixed with DODAB:MO liposomes at various cationic lipid/DNA ratios. The fluorescence of EtBr, which increases upon intercalation into DNA, is measured to assess the extent of pDNA condensation by the cationic liposomes—decreased fluorescence indicates higher compaction efficiency. Heparin and heparan sulfate release assays are also performed to evaluate the percentage of pDNA release from lipoplexes using electrophoresis.
|
| Cell Assay |
For transfection efficiency assessment, 293T mammalian cells are cultured and treated with DODAB:MO lipoplexes prepared at different molar ratios (e.g., 4:1, 2:1, 1:1). Cytotoxicity is evaluated alongside transfection efficiency, with Lipofectamine™ LTX used as a commercial reference standard. Fluorescently-labeled pDNA is used to visualize internalization and nuclear delivery via fluorescence microscopy. For cytokine delivery studies, DODAB:MO (1:2) liposomes encapsulating LIF (0.125 and 0.25 µM) are prepared by lipid film hydration followed by extrusion. Mouse myoblasts are then treated with these formulations for 48 hours, and cell proliferation is measured and compared to free LIF controls. For immunoadjuvant studies, DODAB is dispersed in aqueous solutions by probe sonication to form bilayer fragments. Protein antigens are then mixed with DODAB to form cationic complexes, which are characterized by dynamic light scattering for size and zeta-potential analysis.
|
| Animal Protocol |
In mouse immunization studies, DODAB liposomes or DODAB/protein antigen complexes are administered via intramuscular or subcutaneous injection. Antigen deposition and immune cell exposure are subsequently evaluated. In the guinea pig tuberculosis model, DODAB liposomes containing mycobacterial lipid antigens (Ac2SGL and PIM2) are administered to evaluate bacterial load reduction in spleen and lesion counts in lung and spleen. For assessing cellular immune responses, mice are immunized with DODAB/protein complexes, followed by determination of serum IgG levels by ELISA, delayed-type hypersensitivity reactions measured by footpad swelling tests, and cytokine analysis.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data (absorption, distribution, metabolism, excretion, half-life, oral bioavailability) for DODAB alone have been reported in the available literature. However, DODAB:MO (1:2) liposomal formulations have been shown to protect encapsulated cargo (e.g., LIF) for up to 6 hours when exposed to serum, indicating a stabilizing effect on the payload.
|
| Toxicity/Toxicokinetics |
DODAB is classified as an irritant with hazard statements H315 (causes skin irritation), H319 (causes serious eye irritation), and H335 (may cause respiratory irritation). Recommended personal protective equipment includes dust mask, eyeshields, and gloves. The compound has an RTECS number RG0185984 and hazard code Xi (Irritant). Safety phrases include S26 (in case of contact with eyes, rinse immediately with plenty of water and seek medical advice) and S37/39 (wear suitable gloves and eye/face protection). In cell-based assays, DODAB:MO formulations have demonstrated little toxicity in 293T cells and mouse myoblasts. DODAB is not approved for human or veterinary use and is strictly for research purposes only.
Adverse Effects: Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation. |
| References |
[1]. https://pubchem.ncbi.nlm.nih.gov/compound/77293
|
| Molecular Formula |
C38H80BRN
|
|---|---|
| Molecular Weight |
630.95
|
| Exact Mass |
629.547
|
| Elemental Analysis |
C, 72.34; H, 12.78; Br, 12.66; N, 2.22
|
| CAS # |
3700-67-2
|
| Related CAS # |
Dimethyldioctadecylammonium-d74 bromide;1111808-79-7
|
| PubChem CID |
77293
|
| Appearance |
White to off-white solid powder
|
| Density |
1.047
|
| Melting Point |
~160 °C
|
| LogP |
10.589
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
34
|
| Heavy Atom Count |
40
|
| Complexity |
391
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC.[Br-]
|
| InChi Key |
PSLWZOIUBRXAQW-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
dimethyl(dioctadecyl)azanium;bromide
|
| Synonyms |
Dimethyldioctadecylammonium bromide; DDAB; DODAB; Distearyldimethylammonium bromide; DODA(Br); VSA 3; DSDMAB; 18:0 DDAB; dioctadecyldimethylammonium bromide; Z5T47R065A;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 4 mg/mL (6.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5849 mL | 7.9246 mL | 15.8491 mL | |
| 5 mM | 0.3170 mL | 1.5849 mL | 3.1698 mL | |
| 10 mM | 0.1585 mL | 0.7925 mL | 1.5849 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA